Update upon efficacy and safety of TNF-α inhibitors.
作者： Giuseppe Murdaca , Barbara Maria Colombo , Paola Cagnati , Rossella Gulli , Francesca Spanò
DOI: 10.1517/14740338.2012.630388
关键词: Adalimumab 、 Certolizumab pegol 、 Golimumab 、 Tnf α inhibitors 、 Etanercept 、 Infliximab 、 Medicine 、 Pharmacology 、 Adverse effect 、 Bioinformatics 、 Tumor necrosis factor alpha
摘要: The ongoing progresses in the knowledge of pathogenic mechanisms various immune-mediated and inflammatory diseases as well availability innovative biotechnological approaches have led to development new drugs that add conventional treatments. Among these, tumor necrosis factor (TNF)-α inhibitors, is, infliximab, adalimumab, etanercept, golimumab certolizumab pegol, are now available for clinical use. This editorial discusses recent indications TNF-α pretreatment considerations, reported adverse events and, finally, recommendations its use pregnancy.
elsevier.com
informahealthcare.com参考文章(27)
John Chang, Laila Girgis, Clinical use of anti-TNF-alpha biological agents--a guide for GPs. Australian Family Physician. ,vol. 36, pp. 1035- 1038 ,(2007)
Bernadette M. Saunders, Stephen Tran, Sigrid Ruuls, Jonathon D. Sedgwick, Helen Briscoe, Warwick J. Britton, Transmembrane TNF Is Sufficient to Initiate Cell Migration and Granuloma Formation and Provide Acute, but Not Long-Term, Control ofMycobacterium tuberculosisInfection The Journal of Immunology. ,vol. 174, pp. 4852- 4859 ,(2005) , 10.4049/JIMMUNOL.174.8.4852
Stefan Schreiber, Paul Rutgeerts, Richard N Fedorak, Munaa Khaliq–Kareemi, Michael A Kamm, Michel Boivin, Charles N Bernstein, Michael Staun, Ole Østergaard Thomsen, Alison Innes, CDP870 Crohn’s Disease Study Group, None, A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease Gastroenterology. ,vol. 129, pp. 807- 818 ,(2005) , 10.1053/J.GASTRO.2005.06.064
P Taylor, Antibody therapy for rheumatoid arthritis. Current Opinion in Pharmacology. ,vol. 3, pp. 323- 328 ,(2003) , 10.1016/S1471-4892(03)00032-8
G. Murdaca, B.M. Colombo, F. Puppo, Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs of Today. ,vol. 47, pp. 277- 288 ,(2011) , 10.1358/DOT.2011.47.4.1576692
Eric G. Boyce, Jenana Halilovic, Oby Stan-Ugbene, Golimumab: Review of the Efficacy and Tolerability of a Recently Approved Tumor Necrosis Factor-α Inhibitor Clinical Therapeutics. ,vol. 32, pp. 1681- 1703 ,(2010) , 10.1016/J.CLINTHERA.2010.09.003
Jean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, Michael A Kamm, Andrew P Yu, Eric Q Wu, Paul F Pollack, Kathleen G Lomax, Jingdong Chao, Parvez M Mulani, Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. The American Journal of Gastroenterology. ,vol. 104, pp. 1170- 1179 ,(2009) , 10.1038/AJG.2009.59
Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh, Stanley B. Cohen, Karel Pavelka, Ronald van Vollenhoven, John Sharp, John L. Perez, George T. Spencer-Green, , The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis & Rheumatism. ,vol. 54, pp. 26- 37 ,(2006) , 10.1002/ART.21519
E. William St. Clair, D�sir�e M. F. M. van der Heijde, Josef S. Smolen, Ravinder N. Maini, Joan M. Bathon, Paul Emery, Edward Keystone, Michael Schiff, Joachim R. Kalden, Ben Wang, Kimberly DeWoody, Roberta Weiss, Daniel Baker, , Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis & Rheumatism. ,vol. 50, pp. 3432- 3443 ,(2004) , 10.1002/ART.20568
Paolo Gisondi, Giampiero Girolomoni, Biologic therapies in psoriasis: A new therapeutic approach Autoimmunity Reviews. ,vol. 6, pp. 515- 519 ,(2007) , 10.1016/J.AUTREV.2006.12.002